TrialJAMA ophthalmology2014

Rituximab therapy for refractory orbital inflammation: results of a phase 1/2, dose-ranging, randomized clinical trial.

Eric B Suhler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.